Genentech Pleased With Delay Of FDA's Follow-On Biologics Guidance
This article was originally published in The Pink Sheet Daily
CEO Levinson highlights the debate surrounding follow-on biologics, as well as implementation of the Medicare drug benefit and employee stock option expensing, as three public policy issues "of interest to Genentech."
You may also be interested in...
The cardiologist panel calls for use of the congestive heart failure therapy to be "strictly limited" to patients that present with symptoms in the hospital setting. The expert panel also recommends that Scios "immediately undertake" a professional educational campaign about Natrecor's appropriate uses.
Following the June 6 bid submission deadline, CMS expects to have multiple drug plans in every region. Administrator McClellan declines to provide exact number of Part D bids.
Discussions follow an FDA investigation prompted by journal article reporting 15 cases of non-arteritic anterior ischemic optic neuropathy in sildenafil patients. Pfizer said a review of 103 clinical trials found no reports of the NAION; the company has submitted 23 cases to FDA since Viagra entered the market in 1998.